WEBEnrollment Form Fax: 1-800-604-6027 or E-mail: enrollment@arikares.com Please complete all fields on pages 1 and 3 to prevent any delays and include scanned copies of both sides of the patient’s insurance card (fields marked with an asterisk [*] are mandatory/required). Questions? Phone: 1-833-ARIKARE (1-833-274-5273) Alternate …
WEBArikares Support Program Enrollment Form and Prescription (Rx) (First Shipment Includes Lamira® System) To get started, submit all pages of this form through Fax: 1-800-604-6027 or E-mail: enrollment@arikares.com Please complete all fields on page 1 and 3 to prevent any delays and include scanned copies of both sides of your insurance card
Resources for HCPs - ARIKAYCE
WEBArikares Enrollment Form. To prescribe ARIKAYCE, this form must be completed. Patient signature is required for enrollment in Arikares. Submit via fax (1-800-604-6027) or email (enrollment@arikares.com).
Prescribing ARIKAYCE (amikacin liposome inhalation suspension)
WEBTo prescribe ARIKAYCE, first complete the Arikares ® Enrollment Form with your patients. The Arikares Enrollment Form allows you to both prescribe ARIKAYCE and enroll your patients in the Arikares Support Program. A patient's signature on the Enrollment Form gives them access to support services.
MAC Resources | ARIKAYCE® (amikacin liposome inhalation …
WEBArikares Enrollment Form. Download this form, fill it out, and take it to your doctor’s office to complete.
WEBPROGRAM ENROLLMENT • Complete the Arikares Enrollment Form enclosed or download an interactive form by visiting ArikaresEnrollmentForm.com - Submit all pages via fax (1-800-604-6027) or e-mail (enrollment@arikares.com) PAYER ACCESS EDUCATION • Patient Access Lead (PAL) is available to provide the most recent publicly available
ARIKAYCE® (amikacin liposome inhalation suspension) | Official …
WEBIt’s possible to test MAC-negative. In a clinical study, adding ARIKAYCE to a multidrug treatment helped 29% (65/224) of people with difficult-to-treat MAC (Mycobacterium avium complex) lung disease test MAC-negative at 6 months compared to 8.9% (10/112) of people on a multidrug treatment alone.After 6 months, people on ARIKAYCE did not see an …
FDA approves a new antibacterial drug to treat a serious lung …
WEBFor Immediate Release: September 28, 2018. The U.S. Food and Drug Administration today approved a new drug, Arikayce (amikacin liposome inhalation suspension), for the treatment of lung disease ...
ARIKAYCE® (amikacin liposome inhalation suspension) - Insmed
WEBARIKAYCE is the first and only medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients who have limited or no alternative treatment options. Not actual size. U.S. packaging only.
Taking ARIKAYCE® | ARIKAYCE (amikacin liposome inhalation …
WEBSTEP 5. You’ll receive ongoing support. Both your Arikares Coordinator and your Arikares Trainer are available to provide support and focused education throughout your treatment journey. Call Arikares at 1-833-ARIKARE (1-833-274-5273) or 1-973-437-2376 Monday through Friday from 8 AM to 8 PM ET.
Skip to content